Generic name: BICTEGRAVIR SODIUM 50mg, EMTRICITABINE 200mg, TENOFOVIR ALAFENAMIDE FUMARATE 25mg
Dosage form: tablet
Medically reviewed on September 17, 2018.
Testing When Initiating and During Treatment with BIKTARVY
Prior to or when initiating BIKTARVY, test patients for hepatitis B virus infection [see Warnings and Precautions (5.1)] .
Prior to or when initiating BIKTARVY, and during treatment with BIKTARVY, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.4)].
BIKTARVY is a three-drug fixed dose combination product containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of BIKTARVY is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)] .
Not Recommended in Patients with Severe Renal Impairment
BIKTARVY is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see Use in Specific Populations (8.6)] .
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Biktarvy Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 25 Reviews
- Drug class: antiviral combinations